Venus Remedies Limited's investigational product VRP-034 has received Qualified Infectious Disease Product (QIDP) designation from the US FDA for treating bloodstream infections. VRP-034 is a novel supramolecular cationic formulation of polymyxin B sulphate designed to reduce nephrotoxicity while maintaining efficacy. The QIDP status offers benefits like priority review, fast track eligibility, and extended market exclusivity. Preclinical studies show up to 70% reduction in nephrotoxicity compared to existing polymyxin B treatments, with robust efficacy against resistant pathogens.
25Feb 25
Venus Remedies Secures Exclusive Rights for MET-X: A Potential Game-Changer in Fighting Antibiotic Resistance
Venus Remedies Limited has entered an exclusive license agreement with UK-based Infex Therapeutics to develop MET-X, an innovative metallo-beta-lactamase inhibitor, in India. MET-X, designed to combat drug-resistant Gram-negative bacteria, will be initially combined with meropenem. The company plans to conduct Phase I trials in India, followed by Phase II/III trials for complicated urinary tract infections. This agreement addresses a critical need in India, where meropenem resistance is high and no approved MBL inhibitors exist. The development will adhere to international standards, potentially supporting global commercialization efforts.